Risk of gastric cancer by risk score and risk category
| Risk score | Total number | Gastric cancer* No. (%) | Risk category† | Total number‡ No. (%) | Gastric cancer* No. (%) | Number needed to screen§ |
| Derivation cohort | 9838 (100.0) | 267 (2.7) | 37 | |||
| 0 | 206 | 0 (0.0) | Low (0–11) | 6564 (66.7) | 78 (1.2) | 84 |
| 1 | 107 | 0 (0.0) | ||||
| 2 | 51 | 0 (0.0) | ||||
| 3 | 248 | 0 (0.0) | ||||
| 4 | 857 | 7 (0.8) | ||||
| 5 | 491 | 5 (1.0) | ||||
| 6 | 345 | 1 (0.3) | ||||
| 7 | 639 | 4 (0.6) | ||||
| 8 | 1099 | 12 (1.1) | ||||
| 9 | 917 | 13 (1.4) | ||||
| 10 | 832 | 20 (2.4) | ||||
| 11 | 772 | 16 (2.1) | ||||
| 12 | 687 | 24 (3.5) | Medium (12–16) | 2715 (27.6) | 120 (4.4) | 23 |
| 13 | 775 | 26 (3.4) | ||||
| 14 | 622 | 31 (5.0) | ||||
| 15 | 367 | 19 (5.2) | ||||
| 16 | 264 | 20 (7.6) | ||||
| 17 | 283 | 28 (9.9) | High (>16) | 559 (5.7) | 69 (12.3) | 8 |
| 18 | 141 | 18 (12.8) | ||||
| 19 | 52 | 6 (11.5) | ||||
| 20 | 49 | 12 (24.5) | ||||
| 21 | 25 | 4 (16.0) | ||||
| 22 | 8 | 1 (12.5) | ||||
| 24 | 1 | 0 (0.0) | ||||
| Validation cohort | 5091 (100.0) | 138 (2.7) | 37 | |||
| 0 | 123 | 1 (0.8) | Low (0–11) | 3352 (65.8) | 42 (1.3) | 80 |
| 1 | 46 | 0 (0.0) | ||||
| 2 | 19 | 0 (0.0) | ||||
| 3 | 133 | 1 (0.8) | ||||
| 4 | 424 | 3 (0.7) | ||||
| 5 | 256 | 2 (0.8) | ||||
| 6 | 184 | 2 (1.1) | ||||
| 7 | 302 | 3 (1.0) | ||||
| 8 | 532 | 12 (2.3) | ||||
| 9 | 512 | 7 (1.4) | ||||
| 10 | 429 | 4 (0.9) | ||||
| 11 | 392 | 7 (1.8) | ||||
| 12 | 376 | 15 (4.0) | Medium (12–16) | 1460 (28.7) | 65 (4.5) | 22 |
| 13 | 443 | 11 (2.5) | ||||
| 14 | 317 | 17 (5.4) | ||||
| 15 | 179 | 10 (5.6) | ||||
| 16 | 145 | 12 (8.3) | ||||
| 17 | 130 | 16 (12.3) | High (>16) | 279 (5.5) | 31 (11.1) | 9 |
| 18 | 76 | 5 (6.6) | ||||
| 19 | 32 | 2 (6.3) | ||||
| 20 | 22 | 3 (13.6) | ||||
| 21 | 12 | 4 (33.3) | ||||
| 22 | 4 | 1 (25.0) | ||||
| 24 | 3 | 0 (0.0) |
*The prevalence rate of gastric cancer.
†In both derivation and validation cohorts, there is a significant difference in prevalence of gastric cancer across the three risk categories (p<0.001).
‡Proportion relative to all participants of the derivation or validation cohort.
§Defined as the number of participants who should undergo gastroscopy screening to identify one patient with gastric cancer.